QuidelOrtho Q3 2026: EPS beat masks a revenue miss and deep restructuring
As seen on the 24/7 Wall St. homepage on November 3, 2026.
A 27.3% drop in Point of Care revenue, driven by China pricing reforms and a soft respiratory season, pushed management into an enterprise restructuring targeting more than $80 million in annual savings by 2027. Full-year adjusted EPS guidance narrowed to $0.65 to $0.70.
Continue ReadingShow less
QuidelOrtho's third quarter of 2026 presented two very different stories at once. Adjusted diluted EPS of $0.31 beat expectations against a $0.18 consensus estimate. Revenue of $618.9 million missed expectations and slid 11.6% from the same quarter a year earlier, making clear the profit outperformance did not come from a strengthening business.
The sharpest wound came from Point of Care, where revenue collapsed 27.3% to $119.6 million, dragged down by a soft respiratory season that cut respiratory revenue to $68.8 million from $112.3 million. China compounded the pain: Labs revenue in that market fell to $36.9 million from $67.7 million, a direct result of In Vitro Diagnostics pricing changes imposed by China's National Health Security Administration. Total China revenue dropped 42.7% year over year to $48.4 million.
Not every segment was in retreat. Labs revenue outside China actually grew 3.3%, and Immunohematology held flat at $142.0 million, with CEO Brian J. Blaser noting that those businesses showed 'solid' underlying performance supported by customer relationships and a large global installed base. But those pockets of stability were not large enough to offset the pressure from respiratory weakness and China pricing reforms.
Sponsored
Management's response is a full enterprise restructuring, reorganizing the company around two focused units: Core Diagnostics and Point of Care Diagnostics. The program targets more than $80 million in annual savings by 2027, though investors should expect roughly $30 to $35 million in one-time charges hitting the fourth quarter of 2026. Adjusted EBITDA for Q3 came in at $148.0 million, with margin narrowing to 23.9% from 25.3% a year earlier.
Full-year 2026 guidance was tightened and in some cases cut, with revenue now expected between $2.52 and $2.54 billion, down from a prior ceiling of $2.60 billion. Adjusted diluted EPS guidance narrowed to $0.65 to $0.70, compressing the top end from a prior range that reached $0.90. Management does not expect China or respiratory conditions to meaningfully recover before year-end.
QuidelOrtho beat consensus in six of the eight most recent quarters shown, but the magnitude of beats and misses has been volatile, with a reported loss of $0.04 against a $0.36 estimate in Q1 2026 standing out as a particularly rough period just two quarters ago. The Q3 beat is real, and investors will be watching whether the restructuring can deliver consistent profitability instead of quarter-to-quarter swings driven by seasonal and geographic factors outside the company's control.
Sources
Mentioned: QDEL